SC-236

SC-236 is a potent, selective, orally active small molecule inhibitor of cyclooxygenase‑2 (COX‑2), with an IC50 of approximately 10 nM and over 1700-fold selectivity for COX‑2 over COX‑1. It has been studied primarily in preclinical and experimental settings for its anti-inflammatory, analgesic, and antineoplastic properties. In addition to inhibiting COX‑2 activity, some studies suggest it may act as a peroxisome proliferator–activated receptor gamma (PPARγ) agonist and suppress activator protein–1 (AP‑1) via c-Jun N-terminal kinase pathways. It was an early structural lead that contributed to the development of celecoxib. Indications explored include cancer therapy, lower back pain, osteoarthritis, and general inflammation[1][3][4][6].

Other names

4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamidecompound 1f [PMID: 9135032]CID9865808CID-9865808CID 9865808